Knowthestock.com
CRNX - Crinetics Pharmaceuticals, Inc.
Compare

Sell

Weak Growth●Earnings/Profit is Negative

24%

based on last 5 year data.
Income Statement is WEAK
Revenue Growth is -76.29%
Operating Income is Negative
Net Income is Negative
Earnings Per Share (EPS) is Negative
Net Margin is -17020.41%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 21.98
Debt Ratio is 0.07
Current Debt to Net Income Ratio not available
Total Debt to Total Assets Ratio is 0.0
Cash Flow
Cash from Operations is Negative
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Crinetics Pharmaceuticals, Inc. (CRNX) - http://www.crinetics.com
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Exchange - NASDAQ
Industry - Pharmaceuticals: Major
Sector - Health Technology
CEO - Scott R. Struthers
Employees - 68
    Close
Cookie Policy
Disclaimer
Privacy Policy
Terms of Service
About Us
Contact Us
Help
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.